NHS England marked the first anniversary of the STOMP project on Tuesday 04 July with a review of the year and the launch of a play by the MiXIT theatre group in Newcastle. The group includes people with a learning disability, autism or both and shows the effects that over-medication can have on the health and wellbeing of individuals and their families.
Data-Ed Slides: Best Practices in Data Stewardship (Technical)DATAVERSITY
In order to find value in your organization's data assets, heroic data stewards are tasked with saving the day- every single day! These heroes adhere to a data governance framework and work to ensure that data is: captured right the first time, validated through automated means, and integrated into business processes. Whether its data profiling or in depth root cause analysis, data stewards can be counted on to ensure the organization's mission critical data is reliable. In this webinar we will approach this framework, and punctuate important facets of a data steward’s role.
Learning Objectives:
- Understand the business need for a data governance framework
- Learn why embedded data quality principles are an important part of system/process design
- Identify opportunities to help drive your organization to a data driven culture
Data-Ed Slides: Best Practices in Data Stewardship (Technical)DATAVERSITY
In order to find value in your organization's data assets, heroic data stewards are tasked with saving the day- every single day! These heroes adhere to a data governance framework and work to ensure that data is: captured right the first time, validated through automated means, and integrated into business processes. Whether its data profiling or in depth root cause analysis, data stewards can be counted on to ensure the organization's mission critical data is reliable. In this webinar we will approach this framework, and punctuate important facets of a data steward’s role.
Learning Objectives:
- Understand the business need for a data governance framework
- Learn why embedded data quality principles are an important part of system/process design
- Identify opportunities to help drive your organization to a data driven culture
A Reference Process Model for Master Data ManagementBoris Otto
The management of master data (MDM) plays an important role for companies in responding to a number of business drivers such as regulatory compliance and efficient reporting. With the understanding of MDM’s impact on the business drivers companies are today in the process of organizing MDM on corporate level. While managing master data is an organizational task that cannot be encountered by simply implementing a software system, business processes are necessary to meet the challenges efficiently. This paper describes the design process of a reference process model for MDM. The model design process spanned several iterations comprising multiple design and evaluation cycles, including the model’s application in three participative case studies. Practitioners may use the reference model as an instrument for the analysis and design of MDM processes. From a scientific perspective, the reference model is a design artifact that represents an abstraction of processes in the field of MDM.
Analytics & Data Strategy 101 by Deko DimeskiDeko Dimeski
- Understand why each company needs solid analytics and data strategy & capabilities
- Typical data problems each company experiences, regardless of the scale
- Core competences and roles
- Analytics products and artefacts
- Analytics Usecases
Cure care and research in English dementia policyshibley
I set out to make current dementia policy in England open to the public. This is the final talk to be given by me, Dr Shibley Rahman, at BPP Law School this evening, on cure, care and research.
Keith Ridge, CBE Chief Pharmaceutical Officer
Presentation from the Winterbourne Medicines Programme Launch held in London on 10 September 2014
Ensuring safe, appropriate and optimised use of medication for people with learning disabilities who demonstrate behaviour that can challenge
Improving quality, safety and lives - the Patient Safety Collaborative Programme 2014-2019
Presentation from Chief Nursing Officer for England's Summit 2014
26 November 2014
How can and should Health Psychology and Public Health interact? What has been done so far? This is a keynote to the NHS Education for Scotland Trainee Health Psychologist Programme event in Stirling on 21st March 2018
A Reference Process Model for Master Data ManagementBoris Otto
The management of master data (MDM) plays an important role for companies in responding to a number of business drivers such as regulatory compliance and efficient reporting. With the understanding of MDM’s impact on the business drivers companies are today in the process of organizing MDM on corporate level. While managing master data is an organizational task that cannot be encountered by simply implementing a software system, business processes are necessary to meet the challenges efficiently. This paper describes the design process of a reference process model for MDM. The model design process spanned several iterations comprising multiple design and evaluation cycles, including the model’s application in three participative case studies. Practitioners may use the reference model as an instrument for the analysis and design of MDM processes. From a scientific perspective, the reference model is a design artifact that represents an abstraction of processes in the field of MDM.
Analytics & Data Strategy 101 by Deko DimeskiDeko Dimeski
- Understand why each company needs solid analytics and data strategy & capabilities
- Typical data problems each company experiences, regardless of the scale
- Core competences and roles
- Analytics products and artefacts
- Analytics Usecases
Cure care and research in English dementia policyshibley
I set out to make current dementia policy in England open to the public. This is the final talk to be given by me, Dr Shibley Rahman, at BPP Law School this evening, on cure, care and research.
Keith Ridge, CBE Chief Pharmaceutical Officer
Presentation from the Winterbourne Medicines Programme Launch held in London on 10 September 2014
Ensuring safe, appropriate and optimised use of medication for people with learning disabilities who demonstrate behaviour that can challenge
Improving quality, safety and lives - the Patient Safety Collaborative Programme 2014-2019
Presentation from Chief Nursing Officer for England's Summit 2014
26 November 2014
How can and should Health Psychology and Public Health interact? What has been done so far? This is a keynote to the NHS Education for Scotland Trainee Health Psychologist Programme event in Stirling on 21st March 2018
Anne Webster, -Clinical Lead Winterbourne Projects, NHS England,
Joanne McDonnell - Senior Nurse for Mental Health and Learning Disabilities, NHS England
Neil Hoskin - Expert by Experience, NHS England
Presentation from the Winterbourne Medicines Programme Launch held in London on 10 September 2014
Ensuring safe, appropriate and optimised use of medication for people with learning disabilities who demonstrate behaviour that can challenge
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
2. www.england.nhs.uk/learningdisabilities
The core message
Public Health England says every day about
30,000 to 35,000 adults with a learning
disability are being given psychotropic
medicines when they do not have a diagnosed
mental health condition. This is often to
manage behaviour which is seen as
challenging.
It includes medicines used to treat psychosis,
depression, anxiety, sleep disorders and
epilepsy medication when it is only used for its
calming effect, rather than to treat epilepsy.
Unnecessary use of these drugs, puts people
at risk of significant weight gain, organ failure
and even premature death.
www.england.nhs.uk/stomp
3. www.england.nhs.uk/learningdisabilities
STOMP brings together a wide range of
people:
• People, their families and support
organisations
• Health, education and social care
professionals
• Health, education and social care
providers
• People who buy services eg.
commissioners
• People who check or monitor services
• People who provide health or social care
training
working together
www.england.nhs.uk/stomp
4. www.england.nhs.uk/learningdisabilities
Aims
1. Improve the quality of life of children, young
people and adults with a learning disability,
autism or both, who are prescribed
psychotropic medicines.
2. Make sure people are only given them
for the right reason, in the right amount,
for as short a time as possible.
3. Improve everyone’s understanding of these
medicines and give everyone the
confidence to ask why they are needed.
4. Improve understanding of non-drug
treatments and support which may help.
5. Make sure the person with their family and
paid carers are involved in any decisions to
start, stop, reduce or continue taking them.
www.england.nhs.uk/stomp
5. www.england.nhs.uk/learningdisabilities
Why STOMP?
• They are not always the right answer
• They can have major side effects
• They can reduce people’s quality of life
• They can be used as a type of restraint
• When people are drugged up the world
passes them by.
• This is a human rights issue
When are they right?
• Psychotropic medicines can have an
important role in treating many mental
health conditions when they are used well.
• Sometimes they are right if the person is at
severe risk of harming themselves or others
• As long as other treatments and therapy are
happening so that people will not need them
for long
www.england.nhs.uk/stomp
6. www.england.nhs.uk/learningdisabilities
Pledge
The STOMP pledge was signed in
June 2016 by
• Royal Colleges of Nursing,
Psychiatrists and GPs
• Royal Pharmaceutical Society
• British Psychological Society
• NHS England
• The Minister Alistair Burt
They pledged to work together and
with people with a learning disability
and their families, to take real and
measurable steps to stop over
medication.
3 year campaign up to 2019www.england.nhs.uk/stomp
7. www.england.nhs.uk/learningdisabilities
• Royal College of Speech and Language
Therapy
• British Association Of Social Workers
• Learning Disability Professional Senate:
Care Quality Commission, Clinical
Commissioning Groups, Challenging Behaviour
Foundation, Department of Health, Health
Education England, clinicians - art therapists,
psychologists, occupational therapists,
physiotherapists, dietitians, psychiatrists, GPs,
social workers, speech therapists and learning
disability nurses
• British Association of Music Therapy
• Voluntary Organisations Disability Group
More pledges made in 2017
www.england.nhs.uk/stomp
8. www.england.nhs.uk/learningdisabilities
• All the pledge partners are
working with their members to
promote the pledge, raise
awareness and introduce good
practice through methods such as:
• education programmes, pilot
schemes, presentations, articles in
journals, review of professional
roles, national conferences,
sharing guidelines and partnership
work
Reaching people, changing practice
www.england.nhs.uk/stomp
9. www.england.nhs.uk/learningdisabilities
• Partnership working with health,
social care, voluntary and charity
organisations, family and self
advocacy.
• Partners include the Challenging
Behaviour Foundation (CBF), Care
Management Group (CMG),
Voluntary Organisations Disability
Group (VODG) and the National
Development Team for Inclusion
(NDTi) Learning Disability England,
ARC England, and Skills for Care
www.england.nhs.uk/stomp
partnership working
10. www.england.nhs.uk/learningdisabilities
• Challenging Behaviour Foundation (CBF)
engaged with over 100 families on their
experiences of over medication and what
information and support they need.
• CBF published a report in May 2017 and have
also been commissioned to develop a
medicines pathway document for families and
online resource that will be launched in 2017
• NHS England has also commissioned Change
to engage with people with learning disabilities
and autism who produced a report
• Easy read materials commissioned and more
being developed
• NHS England commissioned MIXIT an
inclusive theatre group to develop a production
on STOMP – official launch on 4th July
www.england.nhs.uk/stomp
pledge actions
11. www.england.nhs.uk/learningdisabilities
Pledge for social care providers
A pledge for social care
providers led by VODG was
launched in May 2017
Already, more than 100
organisations have signed up
who support over 40,000
people. The pledge includes a
self-assessment and planning
template and can be
downloaded from the VODG
webpage on STOMP
A best practice guide produced
by the Care Management Group
(CMG) was launched in the
House of Commons on June 13
by Normal Lamb, MP
www.england.nhs.uk/stomp
12. www.england.nhs.uk/learningdisabilities
• Centre for Pharmacy Post-graduate Education –
online learning for pharmacists launched in October
2016. The course develops awareness,
understanding and key skills to help pharmacists
deliver high quality care to people with learning
disabilities, autism, families and carers. This was
sent to 65,000 pharmacy staff across England and In
2017, over 3000 pharmacists have been trained to
support STOMP
• Five-week pharmacy campaign on learning
disabilities including Facebook live, daily challenges
and Twitter chat. 685 took part.
• Specialist pharmacists and medical colleagues
reviewing prescribing for people with learning
disabilities, autism or both in the North East of
England, Hertfordshire and Manchester
• NHS England has appointed 3 pharmacists to a job-
share role and a family carer is working as a STOMP
adviser
pledge actions
www.england.nhs.uk/stomp
13. www.england.nhs.uk/learningdisabilities
• Royal College of Nursing (RCN) guidance
for pre-registration education students
(across all branches) on learning
disabilities includes a section on over-
medication. Online and hard copy
resource.
• RCN worked with Royal College of
Psychiatrists on good practice guidance on
psychotropic drug prescribing
• British Psychological Society articles on
STOMP in bulletins, Clinical Psychology
Forum, Division AGM and chair’s report.
Promoting alternatives to medication,
prescribing practice and the use of
Positive Behaviour Support (PBS) to
membership and other professional groups
www.england.nhs.uk/stomp
pledge actions
14. www.england.nhs.uk/learningdisabilities
• Royal College of GPs has updated and
published Step by Step guide for annual
health checks. This includes advice on
medication reviews and the need to reduce
psychotropic medication
• NHS England published an updated guide
for GPs and others who prescribe June
2017
• Royal College of Psychiatrists (RCP)
launched an online survey for members
about STOMP
• RCP hosted a joint conference with the
Challenging Behaviour Foundation
• The RCP has produced guidance on the
use of anti-epilepsy drugs for the
management of behaviour problems
www.england.nhs.uk/stomp
pledge actions
15. www.england.nhs.uk/learningdisabilities
• Care and Treatment Reviews (CTRs) –
New NHS England policy and tools
include a section on reviewing the use of
psychotropic medication
• Annual Health Checks (AHCs) –
NHS England worked with partners to
refresh and publish a new annual health
check template which now includes
psychotropic medication reviews.
• July 2017 launch of ‘Better health for
people with learning disabilities - What
social care providers can do to help
people with learning disabilities get
health checks’
https://www.vodg.org.uk/news/launch-of-
innovative-film-to-support-better-health-
for-people-with-learning-disabilities/
www.england.nhs.uk/stomp
pledge actions
16. www.england.nhs.uk/learningdisabilities
• Public Health England Learning Disability
Observatory – June 2017. Pharmacy Guidance on
best practice for supporting people with learning
disabilities
• NHS England has commissioned Public Health
England to carry out four studies a year from
autumn 2017. To show if fewer psychotropic drugs
are being prescribed as awareness of STOMP
improves.
• CQC- have reviewed their inspection framework in
light of STOMP to include checking use of
psychotropic medicines
• A Children and Young People’s STOMP sub-group
has been established.
• NHS England Regions each have an action plan on
STOMP working with local areas
www.england.nhs.uk/stomp
pledge actions
17. www.england.nhs.uk/learningdisabilities
• Raising awareness – STOMP presented at many
national, regional and local events and conferences
eg. in 2017 - One Year On national launch July,
Positive Choices Conference for learning disability
student nurses, STOMP workshop at the NHS
England national ‘Better Health, Better Lives’
conference
• Social media coverage from events and
publications. NHS England has also shared case
studies through Twitter eg.
www.england.nhs.uk/learning-disabilities/stopping-
andrews-psychotropic-medication-in-hertfordshire
• STOMP web information being improved by
NHS England and other pledge partners
www.england.nhs.uk/stomp
pledge actions
18. www.england.nhs.uk/learningdisabilities
“Every person who is taking psychotropic medication will
have their own STOMP action plan.”
”We will ensure that everyone who is on medication for
behaviours that may present as challenging has a
positive behaviour support plan.”
”We will audit the use of psychotropic medication on a
quarterly basis”.
Quotes: Social Care Pledges
19. www.england.nhs.uk/learningdisabilities
“Questions about the use of psychotropic medication will
be included in trustee visits to services.”
”We will ensure that everyone has easy-read information
regarding their medication.”
.
“We will include STOMP in our staff induction.”
“We will use video conferencing to involve families who
live far away in decisions about medication.”
Quotes: Social Care Pledges
20. www.england.nhs.uk/learningdisabilities
“Stomp is important as we have got to make
sure that people aren’t overmedicated. If they
are this can cause physical health problems,
and it can stop people being discharged from
hospital. It can also stop people being able to
take part in decisions about their future life. It’s a
huge issue.”
Jenny Carter- Director- “Together All Are Able” & Expert
by Experience- working with Pathways Associates
statement of support
21. www.england.nhs.uk/learningdisabilities
“The Royal College of Psychiatrists and the
Learning Disability Professional Senate are
determined to make STOMP happen. We will work
in our Learning Disability Teams and with General
Practice colleagues to reduce the harm caused by
inappropriate use of psychotropic medication. We
will promote comprehensive monitoring of
medication, and the timely use of evidence based
psychosocial interventions.”
Dr Ashok Roy
Chair, Faculty of Intellectual Disability Psychiatry, The Royal College
of Psychiatrists and Co-chair Learning Disability Professional
Senate
statement of support
22. www.england.nhs.uk/learningdisabilities
The Learning Disability Professional Senate pledges our
commitment to supporting this initiative. This is about
fundamentally rethinking the role of psychotropic drugs
for the management of behaviours that challenge in
learning disabilities.
We fully endorse that it is the role of all professions to
challenge medication issues and to provide alternative
psychological and other therapeutic interventions for
behaviours that challenge, using a Positive Behaviour
Support framework.
pledge commitment
23. www.england.nhs.uk/learningdisabilities
“ Josh used to be prescribed a number of anti-psychotic
and sedative type medications when he was in hospital
far away from home. He has now come off virtually all of
these drugs. I have seen Josh improve physically and
emotionally. He seems more alert and, in my opinion, his
long term memory, of places and people has improved
greatly.”
Phil Wills, dad of Josh Wills age 16 who has autism and a learning
disability and who was in an assessment and treatment unit for
three year, and who was discharged to a tailored package of
education, health and care in November 2015
statement of support
24. www.england.nhs.uk/learningdisabilities
Bringing Us Together’s project Stronger Together has been working
with NHS England and families across the country to have their views
listened to, acted upon and for families to take an active part in
changing policy and practice. Families who have loved ones in
Assessment and Treatment Units and hospital settings have been
determined over recent years to make a difference to the lives of their
own children and young people whilst at the same time making sure
that young people don’t end up in crisis, sent out of their communities
and into inappropriate settings where we have heard heart breaking
stories of the overuse of medication leading to a downward
spiral. Families are absolutely behind this campaign as they know
that over reliance on medication may cause substantial side
effects. As one parent told us “STOMP could mean that a person’s
condition is treated respectfully and holistically rather than
automatically given drugs to keep them quiet and sedated”. We will
continue to support STOMP and congratulate all those involved in
raising awareness of this very important issue.
For more information www.bringingustogether.org.uk
statement of support
25. www.england.nhs.uk/learningdisabilities
Raising awareness of STOMP amongst the Speech &
Language Therapy profession as a whole and in doing
so:
• Promote a better understanding and response to the
communication needs of people with a LD in order to
reduce challenging behaviour and the current over reliance
on medication
• We will use the 5 Good Communication Standards to
empower people in understanding their medication ,
helping carers to know how service users can be
proactively involved in their reviews and therefore
decisions about their medication
RCSLT commitment
Editor's Notes
CARL
Reference: Public Health England (2015) Prescribing of psychotropic medication to people with learning disabilities and/or autism by general practitioners in England, London: Public Health England.
In 2015 Public Health England estimated that, on an average day in England, between 30,000 and 35,000 adults with a learning disability are being prescribed an antipsychotic, an antidepressant or both without an appropriate clinical reason.
Unnecessary use of these drugs, puts people at risk of significant weight gain, organ failure and premature death.
Is one of these 35,000 people your patient? Stop this happening and take action today. Check and review your patients immediately to ensure another day of potential harm doesn’t go by.
-Prescribing Observatory for Mental Health: Nationally, over 60% of people with a learning disability who are seeing a psychiatrist, are being prescribed an antipsychotic drug but only half of these have the diagnosis of a psychotic mental illness that these drugs were developed to treat
Ask people what they think of this message. Is it strong enough? Should it be stronger?